Bausch + Lomb Announces 23 Scientific Presentations at the 2024 Tear Film and Ocular Surface Society Conference

VAUGHAN, Ontario, Oct. 29, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 23 planned scientific presentations during the Tear Film and Ocular Surface Society Conference, which will take place in Venice, Italy, October 30 through November 2, 2024. Bausch + Lomb is also the conference Title Sponsor, reflecting a global commitment to innovation and education in the field of dry eye.

Multiple presentations will feature new data evaluating MIEBO® (perfluorohexyloctane ophthalmic solution), which was launched in September 2023 in the U.S. These presentations build upon the wealth of insights highlighting MIEBO’s efficacy and safety, and will feature new findings showing early symptom relief and satisfaction in patients with dry eye disease (DED). In addition, new research further describes the XIIDRA® (lifitegrast ophthalmic solution) 5% mechanism of action in dry eye disease as well as its compatibility with contact lens wear and use prior to cataract surgery. XIIDRA was designed to target inflammation, a key factor in the development and progression of DED.

Mechanism of action data for LUMIFY® redness reliever eye drops will also be shared, as well as data comparing Blink® Triple Care lubricating eye drops, with an existing lubricating eye drop.

Educational sessions will feature innovations in clinical diagnosis and treatment of dry eye, with emphasis on technological advancements.

The complete list of Bausch + Lomb poster presentations:

  • "Quantitative and Qualitative Assessment of Real-World Lifitegrast Usage in Patients with Dry Eye Disease" Starr et al.
  • "The Mechanism of Action of Leukocyte Function-Associated Antigen (LFA-1) Antagonist Lifitegrast in Dry Eye Disease" Hamrah et al.
  • "Safety of Lifitegrast in Patients with Dry Eye Disease: Analysis of a Postmarketing Database" Quint et al.
  • "The Effect of Lifitegrast 5.0% Solution on Clinical Signs and Biomarkers in Dry Eye Disease" Karpecki et al.
  • "Do Symptomatic Contact Lens Wearers Benefit from Using Lifitegrast" Schulze et al.
  • "Treatment of Dry Eyes with Lifitegrast 5% Prior to Cataract Surgery: A Prospective Trial" Yang et al.
  • "Early Adoption and Utilization of Perfluorohexyloctane for Dry Eye Disease" Shen Lee et al.
  • "Perfluorohexyloctane Ophthalmic Solutions Instillation Comfort and Eyedrop Acceptability: Patient-Reported Outcomes in Phase 3 Clinical Studies" Gupta et al.
  • "Perfluorohexyloctane Ophthalmic Solution for Dry Eye Disease: A Comparison of Safety and Efficacy Across Phase 2 and 3 Clinical Trials" Gupta et al.
  • "Early Symptom Relief and Satisfaction with Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease: Results from a Prospective, Multicenter Study" Gupta et al.
  • "Effect of Perfluorohexyloctane Ophthalmic Solution on Corneal Staining in Patients with Dry Eye Disease" Quint et al.
  • "Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution" Benitez Del Castillo et al.
  • "Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution" Benitez Del Castillo et al.
  • "Ocular Vasoconstrictors: Does Mechanism of Action Make a Difference?" Doan et al.
  • "Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop" Lee et al.
  • "Conjunctival Hyperaemia: Healthcare Professionals’ Perspectives on the Treatment Landscape in Europe" Doan et al.
  • "Intervening in the Dry Eye Inflammatory Cycle with a Novel Nutritional Supplement" Tong et al.
  • "Novel Oral Supplement Improved Dry Eye Symptoms and Tear Volume: Results from a Randomized Clinical Trial" Tong et al.
  • "Using Narrative Medicine to Identify Key Factors Affecting Quality of Life in Dry Eye Disease" Aragona et al.
  • "Comparison of Two Preservative-Free Artificial Tears with Sodium Hyaluronate for Relief of Dry Eye: Multicentre Trial Findings" Labetoulle et al.
  • "Evaluating Dehydration Kinetics of Kalifilcon A and Other Contact Lens Materials Using Water Kinetics Coefficients" Rizzo et al.
  • "Evaluation of Meibomian Gland Loss: Comparison Between Grading Scale and Semi-Automated Computerized Classification" Rizzo et al.
  • "Hyperosmolarity is Associated with Increased Variation of Light Scatter Following Cataract Surgery" Sullivan et al.

###

INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • Patients should remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting.
  • It is important for patients to use MIEBO exactly as prescribed.
  • It is not known if MIEBO is safe and effective in children under the age of 18.
  • The most common eye side effect seen in studies was blurred vision (1% to 3 % of patients reported blurred vision and eye redness).

Click here for full Prescribing Information for MIEBO.

WHAT IS XIIDRA?
XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • Do not use XIIDRA if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.
  • The most common side effects of XIIDRA include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation.
  • To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using XIIDRA and wait for at least 15 minutes before placing them back in your eyes.
  • It is not known if XIIDRA is safe and effective in children under 17 years of age.

Click here for full Prescribing Information for XIIDRA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Media Contact:
Caryn Marshall
[email protected]
(908) 493-1381

Investor Contact:
George Gadkowski
[email protected]
(877) 354-3705 (toll free)
(908) 927-0735

Back to Press Releases